WC
ODT

Wexford Capital’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Wexford Capital’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,832
Closed -$54K – 400
2020
Q4 		$54K Buy
+2,832
New +$43.7K 0.01% 167

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Wexford Capital's ODT Position: Q1 2021 in Review

Wexford Capital sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2021, closing a stake of 2,832 shares — an estimated $54K sold.

Wexford Capital first reported a position in ODT in Q4 2020 and held it in 1 quarter. The position peaked at $54K in Q4 2020. 83 funds tracked by Wall St. Rank hold ODT as of Q1 2021.

  • Wexford Capital reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 2,832 Odonate Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $54K.
  • Wexford Capital first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Wexford Capital's Odonate Therapeutics, Inc. Common Stock position peaked at $54K in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.